Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight-loss drugs may be no obesity silver bullet
Sir Keir Starmer and his health secretary have been lauding the potential of the new generation of weight-loss drugs. Given as regular injections, the treatments – Wegovy and Mounjaro – mimic a hormone that makes people less hungry.
Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out.
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.
Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Key Takeaways Hims & Hers shares gained Monday after the Food and Drug Administration said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage.
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
The FDA has agreed to review its decision to remove Eli Lilly’s LLY tirzepatide — the active ingredient used in diabetes drug Mounjaro and obesity drug Zepbound — from its shortage list. During this process,
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
Hims & Hers up 10% as FDA reconsiders taking Lilly weight loss drug off shortage list
Hims & Hers Health (NYSE:HIMS) is up ~10% in Monday morning trading following a recent lawsuit challenging the U.S. FDA's decision to remove Eli Lilly's (NYSE:LLY) tirzepatide from a drug shortages list.
23h
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
17h
What are weight loss jabs and how do they work?
BBC reporter Charlie Buckland explains what they are and how they work.
1d
on MSN
Study: GLP-1 weight-loss drugs might lower, not increase, teen suicide risk
In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and ...
9h
on MSN
NHS cannot keep up with ‘tidal wave’ of demand for weight-loss drugs
The NHS cannot meet the “tidal wave” of demand for weight-loss jabs, medics say.A report calling for a review of existing ...
6d
1 in 10 Americans have tried injectable weight loss medication—These are the cities with the most early adopters
Three cities in Hawaii, Minnesota, and Texas report the highest usage of injectable weight loss medications. Meanwhile, ...
11h
Could weight-loss drugs get people back to work? UK wants to find out
Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.
5d
on MSN
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...
6d
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback